[Syngeneic hematopoietic stem cell transplantation for aplastic anemia]
Y Zhang1, D L Yang1, R L Zhang1
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|August 12, 2021
Summary
Syngeneic hematopoietic stem cell transplantation (HSCT) shows a high survival rate for aplastic anemia patients. Graft failure remains a significant challenge despite successful engraftment in most cases.
Area of Science:
- Hematology
- Transplantation Immunology
Background:
- Aplastic anemia (AA) is a rare but serious condition characterized by bone marrow failure.
- Hematopoietic stem cell transplantation (HSCT) is a potential curative treatment for AA.
Purpose of the Study:
- To assess the effectiveness and long-term outcomes of syngeneic HSCT in treating aplastic anemia.
- To identify challenges associated with this treatment modality.
Main Methods:
- Retrospective analysis of clinical data from 11 patients with aplastic anemia who underwent syngeneic HSCT.
- Evaluation of engraftment times, long-term graft stability, survival rates, and complications.
Main Results:
- All 11 patients achieved initial engraftment (neutrophils and platelets) after syngeneic HSCT.
- Eight patients experienced long-term stable engraftment, with 9 patients showing normal blood counts long-term.
- Three patients encountered graft failure, with one achieving stable engraftment after a second transplant.
Conclusions:
- Syngeneic HSCT offers a favorable long-term survival rate for aplastic anemia.
- Graft failure is the primary obstacle to successful outcomes in syngeneic HSCT for AA.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
585
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
585
01:21Stem Cell Therapy for Tissue Regeneration
4.3K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.3K
01:22iPS Cell Differentiation
2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K
01:01Regulation of Hematopoietic Stem Cells
3.5K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.5K